December 2012 - Volume 18 - Issue 12
pp: 2203-2416

Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience

Kane, S. V.; Horst, S.; Sandborn, W. J.; More

Inflammatory Bowel Diseases. 18(12):2203-2208, December 2012.

Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines

Zisman, Timothy L.; Bronner, Mary P.; Rulyak, Stephen; More

Inflammatory Bowel Diseases. 18(12):2240-2246, December 2012.

Contribution of higher risk genes and European admixture to Crohn's disease in African Americans

Wang, Ming-Hsi; Okazaki, Toshihiko; Kugathasan, Subra; More

Inflammatory Bowel Diseases. 18(12):2277-2287, December 2012.

Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups

Cheifetz, A. S.; Melmed, G. Y.; Spiegel, B.; More

Inflammatory Bowel Diseases. 18(12):2294-2300, December 2012.

Original Clinical Articles

Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: Prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal...

Lenze, Frank; Wessling, Johannes; Bremer, Janbernd; More

Inflammatory Bowel Diseases. 18(12):2252-2260, December 2012.

Original Basic Science Articles

Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases

Harris, Alan R.; Nagy-Szakal, Dorottya; Pedersen, Natalia; More

Inflammatory Bowel Diseases. 18(12):2334-2341, December 2012.

CommonNOD2risk variants in African Americans with Crohn's disease are due exclusively to recent Caucasian admixture

Adeyanju, Oloruntosin; Okou, David T.; Huang, Clifton; More

Inflammatory Bowel Diseases. 18(12):2357-2359, December 2012.

1 2 3 4 5